title: 5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.
abstract: Adrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a significant effort has been made to develop multinational, collaborative studies to better understand the pathogenesis and clinical features of this rare disease in attempt to improve the therapeutic strategies and patient outcome. The results of both standard and newer treatments are discussed in this review as well as the recent discovery of pathways involved in ACC pathogenesis that provide the rationale to introduce new molecular target therapies. Finally, remaining issues regarding how to improve available therapies in adjuvant setting are raised and addressed.
authors.affiliation: Departamento de Endocrinologia da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Unidade de Oncologia Endócrina do Instituto do Câncer do Estado de São Paulo (ICESP), Av Dr. Arnaldo, 251 - 5 andar, São Paulo, SP, 01246-000, Brazil. ana.hoff@icesp.org.br.
authors.forename: Ana O
authors.initials: AO
authors.lastname: Hoff
authors.affiliation: Dipartimento di Specialità Medico-Chirurgiche, Scienze Radiologiche e Sanità Pubblica Università degli Studi di Brescia, Oncologia Medica, Azienda Ospedaliera Spedali Civili, Brescia, Italy.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy*; D018268:Adrenocortical Carcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D006801:Humans; D020360:Neoadjuvant Therapy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents